Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology

Why Is Genetic Testing Needed to Confirm an HNPP Diagnosis?

At a Glance

EMG and nerve conduction studies can suggest HNPP by showing nerve slowing at multiple pressure points, but they cannot prove the cause. Genetic testing, usually for a PMP22 deletion or variant, confirms HNPP and helps guide treatment, surgery, and family counseling.

Electrodiagnostic testing—often referred to generally as an EMG and nerve conduction study—can show where your nerves are struggling, but it cannot definitively prove why. Because the nerve slowing seen in Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) can mimic common conditions like carpal tunnel syndrome or an autoimmune disease called CIDP, a genetic test is the gold standard for confirming the diagnosis. Confirming the genetic cause helps ensure you get the right advice, provides clarity for your family, and protects you from inappropriate treatments.

What Nerve Tests Can (and Cannot) Tell You

When you undergo electrodiagnostic testing, the doctor uses nerve conduction studies (NCS) to measure how fast electrical signals travel through your nerves, and an electromyogram (EMG) to evaluate muscle electrical activity. In HNPP, the protective coating of the nerve (myelin) is fragile, making nerves vulnerable at natural pinch points like the wrist or the elbow [1][2].

However, finding focal slowing (a delay in the nerve signal at a single pinch point) is incredibly common in the general population. If a doctor only tests your symptomatic arm, the results might look identical to standard carpal tunnel syndrome or cubital tunnel syndrome [2][3].

Testing becomes highly suspicious for HNPP when it reveals a multifocal pattern—meaning there is nerve slowing at multiple compression sites, even in nerves where you currently have no symptoms [4][2]. Yet, even this broader pattern is just a strong clue. It takes a genetic test to definitively identify the root cause [3].

Why Confirming the Diagnosis Matters

Without genetic confirmation, the symptoms and test results of HNPP can sometimes be mistaken for other conditions. Getting the diagnosis right changes your care plan.

  • Differentiating from CIDP: HNPP can cause conduction block (where the nerve signal is severely delayed or stopped), a feature it shares with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) [5][6]. CIDP is an autoimmune condition typically treated with immune therapies like IVIG or steroids. While uncommon, there are documented cases of patients with unrecognized HNPP receiving ineffective immune treatments for presumed CIDP before a genetic test corrected the diagnosis [7][8]. (Note: Never stop prescribed immune therapies without first consulting your neurologist, as CIDP requires appropriate and often urgent treatment).
  • Making Informed Surgical Decisions: If your nerve slowing is assumed to be standard carpal tunnel syndrome, a doctor might recommend surgical decompression. People with HNPP can develop standard nerve entrapments and some do benefit from carpal tunnel release. However, surgical outcomes in HNPP patients are highly variable, and decompression is not a cure for the underlying fragility of the nerve [9][10]. Genetic confirmation allows you and your surgeon to carefully weigh the risks, benefits, and alternatives before operating [11].

What the Genetic Test Looks For

To confirm HNPP, your doctor will order a genetic test (usually a simple blood draw or cheek swab) specifically evaluating the PMP22 gene.

  • The PMP22 Deletion: In roughly 80% of confirmed cases, HNPP is caused by a missing piece of genetic code (a deletion) on chromosome 17 that includes the PMP22 gene [12][13]. If this deletion is found in the right clinical context, the genetic cause of your HNPP is strongly confirmed [14].
  • PMP22 Sequencing: A meaningful minority of people with HNPP do not have the full deletion, but rather a sequence variant (a “typo” in the genetic code) within the gene. If your initial deletion test is negative but your doctor still strongly suspects HNPP, they may order gene sequencing to look for these specific variants [15][16].

The Role of Genetic Counseling

Because HNPP is an autosomal dominant condition, a person with the condition has a 50% chance of passing the genetic variant to each of their children. However, symptoms can vary widely—even within the same family, some relatives may be entirely asymptomatic [12][17].

Before and after genetic testing, it is highly recommended to speak with a genetic counselor. They can help you understand what a positive, negative, or “uncertain” result means for you, how to communicate risks to your blood relatives, and the practical implications for family planning and insurance.

Ultimately, a confirmed diagnosis shifts your care team’s focus to what actually helps: protecting your nerves from pressure. This includes practical lifestyle adjustments like avoiding crossing your legs, minimizing repetitive motions, using padded elbow rests, and working with occupational therapy to prevent future palsies [14][11].

Common questions in this guide

Can an EMG or nerve conduction study confirm HNPP on its own?
No. These studies can show nerve slowing at several pressure points and make HNPP more likely, but similar findings can occur with carpal tunnel syndrome, cubital tunnel syndrome, or CIDP. A genetic test is needed to confirm the underlying cause.
What genetic test is used to diagnose HNPP?
A genetic test usually looks for a deletion involving the PMP22 gene on chromosome 17, often using a blood sample or cheek swab. If deletion testing is negative but HNPP remains likely, PMP22 sequencing may look for a smaller gene variant.
Why is it important to distinguish HNPP from CIDP?
HNPP and CIDP can both cause abnormal nerve slowing or conduction block, but CIDP is an autoimmune disease treated with immune therapies such as IVIG or steroids. Confirming HNPP can help avoid ineffective treatment and direct care toward protecting nerves from pressure. Do not stop any prescribed therapy without speaking with your neurologist.
Does a positive HNPP test affect my family?
Yes. HNPP is autosomal dominant, so a person with the condition has a 50% chance of passing the genetic variant to each child. Symptoms can vary widely, and some relatives may have no symptoms, so genetic counseling can help explain testing and family-planning options.
Does an HNPP diagnosis mean I cannot have carpal tunnel surgery?
Not necessarily. People with HNPP can also develop a standard nerve entrapment and may benefit from decompression, but results vary and surgery does not correct the underlying nerve fragility. Your neurologist and surgeon should weigh the test results, symptoms, risks, benefits, and alternatives.
What should I do if my HNPP deletion test is negative?
A negative deletion test does not always rule out HNPP because some people have a smaller PMP22 sequence variant instead. If your symptoms and nerve studies still suggest HNPP, ask your clinician whether PMP22 sequencing or a broader genetic evaluation is appropriate.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Did my nerve conduction study show slowing only at my symptomatic areas, or did you see abnormalities in asymptomatic nerves too?
  2. 2.Are we ordering the specific PMP22 deletion test, or a broader genetic neuropathy panel?
  3. 3.If my initial genetic test is negative, will we proceed with PMP22 sequencing given my symptoms?
  4. 4.How does a confirmed HNPP diagnosis change your approach to considering nerve decompression surgery for me?
  5. 5.Can you refer me to a genetic counselor to discuss how my results might impact my family members?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Electrodiagnostic Characterization of Hereditary Neuropathy With Liability to Pressure Palsies.

    Takahashi S, Chum M, Kimpinski K

    Journal of clinical neuromuscular disease 2017; (18(3)):119-124 doi:10.1097/CND.0000000000000152.

    PMID: 28221301
  2. 2

    Hereditary neuropathy with liability to pressure palsy in patients under 30 years old: Neurophysiological data and proposed electrodiagnostic criteria.

    Robert-Varvat F, Jousserand G, Bouhour F, et al.

    Muscle & nerve 2018; (57(2)):217-221 doi:10.1002/mus.25666.

    PMID: 28407266
  3. 3

    Heterogeneous Presentation of Hereditary Neuropathy With Liability to Pressure Palsies: Clinical and Electrodiagnostic Findings in Three Patients.

    Shields LB, Iyer VG, Zhang YP, Shields CB

    Cureus 2022; (14(12)):e32296 doi:10.7759/cureus.32296.

    PMID: 36628033
  4. 4

    Clinical and neurophysiological findings in patients with hereditary neuropathy with liability to pressure palsy and chromosome 17p11.2 deletion.

    Pabón Meneses RM, Azcona Ganuza G, Urriza Mena J, et al.

    Neurologia 2022; (37(4)):243-249 doi:10.1016/j.nrl.2019.02.005.

    PMID: 31047731
  5. 5

    Hereditary Neuropathy with Liability to Pressure Palsies: A Rare Condition That Presents with Common Symptoms: A Case Report.

    Mota PTD, Maio M, Sapage R, et al.

    JBJS case connector 2018; (8(4)):e95 doi:10.2106/JBJS.CC.18.00132.

    PMID: 30489379
  6. 6

    Are electrophysiological criteria useful in distinguishing childhood demyelinating neuropathies?

    Potulska-Chromik A, Ryniewicz B, Aragon-Gawinska K, et al.

    Journal of the peripheral nervous system : JPNS 2016; (21(1)):22-6 doi:10.1111/jns.12152.

    PMID: 26663344
  7. 7

    Hereditary Neuropathy with Liability to Pressure Palsies Mimicking a Chronic Inflammatory Demyelinating Polyneuropathy Variant: A Case Report Highlighting Diagnostic Challenges.

    Yamamoto M, Hatanaka Y, Kaida K

    Internal medicine (Tokyo, Japan) 2026; (65(9)):1302-1306 doi:10.2169/internalmedicine.5771-25.

    PMID: 41062314
  8. 8

    Acute Demyelinating Polyneuropathy as Presentation of Hereditary Neuropathy With Liability to Pressure Palsies in a Patient Who Exercised Regularly in the Army.

    Perugula M, Uppal G, Chuquilin M

    Journal of clinical neuromuscular disease 2017; (18(4)):228-234 doi:10.1097/CND.0000000000000145.

    PMID: 28538254
  9. 9

    Utility of Carpal Tunnel Release and Ulnar Decompression in CMT1A and HNPP.

    Chompoopong P, Niu Z, Shouman K, et al.

    Muscle & nerve 2022; (66(4)):479-486 doi:10.1002/mus.27687.

    PMID: 35894586
  10. 10

    Hereditary neuropathy associated with liability to pressure palsies: a 24-year experience with carpal and cubital tunnel surgery.

    François T, Davion JB, Deken-Delannoy V, et al.

    The Journal of hand surgery, European volume 2024; (49(2)):257-263 doi:10.1177/17531934231199849.

    PMID: 37717179
  11. 11

    [Hereditary neuropathy with liability to pressure palsies in childhood: Report of three cases].

    Bar C, Villéga F, Espil C, et al.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2017; (24(3)):260-262 doi:10.1016/j.arcped.2016.12.002.

    PMID: 28131554
  12. 12

    Clinical and molecular genetic characteristics of 24 families of hereditary neuropathy with liability to pressure palsy and literature review.

    Cao W, Huang S, Zhao H, et al.

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2023; (48(10)):1572-1582 doi:10.11817/j.issn.1672-7347.2023.230116.

    PMID: 38432886
  13. 13

    Hereditary neuropathy with liability to pressure palsies.

    Attarian S, Fatehi F, Rajabally YA, Pareyson D

    Journal of neurology 2020; (267(8)):2198-2206 doi:10.1007/s00415-019-09319-8.

    PMID: 30989370
  14. 14

    Hereditary neuropathy with liability to pressure palsies misdiagnosed as Guillain-Barré Syndrome: A case report.

    Zhu J, Tong X, Li Y, et al.

    Medicine 2022; (101(38)):e30768 doi:10.1097/MD.0000000000030768.

    PMID: 36197172
  15. 15

    Noncanonical splice-site variant in peripheral myelin protein 22 gene (PMP22) in a patient with hereditary neuropathy with liability to pressure palsies.

    Kawamoto N, Hamada Y, Kobayashi S, et al.

    Journal of the peripheral nervous system : JPNS 2023; (28(3)):513-517 doi:10.1111/jns.12558.

    PMID: 37170477
  16. 16

    A Life-Saving Palsy: Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) Presenting As Hand Weakness during Cardiopulmonary Resuscitation (CPR) Training

    Hughes H, Tubridy N, Connolly S

    Irish medical journal 2018; (111(8)):808.

    PMID: 30547545
  17. 17

    Yield of the PMP22 deletion analysis in patients with compression neuropathies.

    Ivanovic V, Brankovic M, Bjelica B, et al.

    Journal of neurology 2020; (267(12)):3617-3623 doi:10.1007/s00415-020-10052-w.

    PMID: 32642785

This page is for informational purposes only and does not constitute medical advice. A neurologist and genetic counselor should interpret your HNPP test results and discuss treatment or family-planning decisions.

Get notified when new evidence is published on Hereditary neuropathy with liability to pressure palsies.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.